


Methylthiouracil

Cat. No.:	HY-B0513		
CAS No.:	56-04-2		
Molecular Formula:	C ₅ H ₆ N ₂ OS		
Molecular Weight:	142.18		
Target:	NF-κB; TNF Receptor; Interleukin Related; ERK		
Pathway:	NF-κB; Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; Stem Cell/Wnt		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 50 mg/mL (351.67 mM)
 H₂O : < 0.1 mg/mL (insoluble)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	7.0333 mL	35.1667 mL	70.3334 mL
	5 mM	1.4067 mL	7.0333 mL	14.0667 mL
	10 mM	0.7033 mL	3.5167 mL	7.0333 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (17.58 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.5 mg/mL (17.58 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Methylthiouracil is an antithyroid agent. Methylthiouracil suppresses the production TNF-α and IL-6, and the activation of NF-κB and ERK1/2.

IC₅₀ & Target

NF-κB	TNF-α	IL-6	ERK1
ERK2			

In Vitro

HUVECs are treated with various concentrations of MTU (0-20 μM) for 6 h after the addition of LPS (100 ng/mL) for 4 h. MTU

inhibits LPS-mediated hyperpermeability in endothelial cells, with the optimal effect occurring at a concentration above 5 μ M. The effects of MTU are examined on HUVEC actin cytoskeletal arrangement by immunofluorescence staining of HUVEC monolayers with F-actin labeled fluorescein phalloidin. Control HUVECs exhibit a random distribution of F-actin throughout the cells, with some localization of actin filament bundles at the cell boundaries. Barrier disruption by LPS (100 ng/mL) is manifested by the formation of paracellular gaps in HUVECs. In addition, post-treatment with MTU (10 or 20 μ M) results in inhibited formation of LPS-induced paracellular gaps with the formation of dense F-actin rings. To test the cytotoxicity of MTU, cellular viability assays are performed in HUVECs treated with MTU for 24 h. At concentrations up to 20 μ M, MTU does not affect cell viability^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

MTU treatment results in marked inhibition of the peritoneal leakage of dye induced by LPS. The average circulating blood volume for mice is 72 mL/kg. Because the average mouse weight in this study is 27 g, and the average blood volume is 2 mL, the injected MTU (142 or 284 μ g/kg) results in a maximum concentration of 10 or 20 μ M in the peripheral blood^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay ^[1]

MTT is used as an indicator of cell viability. Primary human umbilical vein endothelial cells (HUVECs) are grown in 96-well plates at a density of 5×10^3 cells/well. After 24 h, the cells are washed with fresh medium and treated with MTU (0-20 μ M). After a 48 h incubation period, the cells are washed, and 100 μ L of MTT (1 mg/mL) is added, followed by incubation for 4 h. Finally, DMSO (150 μ L) is added to solubilize the formazan salt formed, and the amount of formazan salt is determined by measuring the OD at 540 nm using a microplate reader ^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration ^[1]

Mice^[1]

Male C57BL/6 mice (6-7 weeks old; average weight, 27 g) are used in this study. Mice are administered LPS (0.3 mg/mouse or 15 mg/kg, intravenously). After 4 h, the mice are intravenously treated with MTU (142 or 284 μ g/kg, for 6 h) and injected with 1% Evans blue dye solution in normal saline. Six hours later, the mice are sacrificed and peritoneal exudates are collected by washing cavities with 5 mL of normal saline and by centrifuging at $200 \times g$ for 10 min. The absorbance of the supernatant is read at 650 nm. Vascular permeabilities are expressed as μ g of dye/mouse that leaked into the peritoneal cavity and are determined using a standard curve.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Ku SK, et al. Anti-inflammatory effects of methylthiouracil in vitro and in vivo. Toxicol Appl Pharmacol. 2015 Nov 1;288(3):374-86.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA